USA: A large retrospective, propensity score–matched cohort study found that ursodeoxycholic acid (UDCA) use in patients with ...

Dublin, Nov. 22, 2023 (GLOBE NEWSWIRE) -- The "Primary Biliary Cholangitis - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering. This report provides ...

DelveInsight’s Primary Biliary Cholangitis Market Insights report includes a comprehensive understanding of current treatment practices, primary biliary cholangitis emerging drugs, market share of ...

Recurrent primary biliary cholangitis (rPBC) occurs in a significant number of patients following liver transplantation for PBC. Various immunosuppressive therapies and ursodeoxycholic acid treatment ...

Using electronic health record data from more than 12,000 PBC patients, investigators found that UDCA use was associated with ...

AMSTERDAM — Patients with an incomplete response to first-line therapy for primary biliary cholangitis are significantly more likely to achieve a complete biochemical response with bezafibrate ...

The cholangitis infection is often caused by bacteria, a gallstone or any another blockage. Primary biliary cholangitis is a chronic condition where inflammation of the bile duct system keeps bile ...

Seladelpar is an oral, selective peroxisome proliferator-activated receptor delta agonist. Treatment with seladelpar was associated with an improvement in cholestatis markers in patients with primary ...

Please provide your email address to receive an email when new articles are posted on . International Primary Biliary Cholangitis Day, celebrated on September 10, aspires to raise awareness of the ...

Seladelpar, an investigational selective agonist of peroxisome proliferator–activated receptor-delta (PPAR-δ), significantly improves liver biomarkers of disease activity and bothersome symptoms of ...

Seven weeks ago, Alison Kavanaugh made the decision to donate part of her liver to her sister, whose liver was failing from a ...